Anti-obesity drugs developed so far The Food and Drug Administration (FDA) in the United States has approved five long-term obesity drugs so far: Lorcaserin (Belviq), Phentermine/Topiramate (Qsymia), Naltrexone/ Bupropion (Contrave), Liraglutide (Saxenda) and Orlistat (Xenical) for the long-term treatment of obesity
Understanding what research actually shows about low-dose effectiveness requires separating initial tolerance from therapeutic response
Before you use it, let the pen sit out at room temperature for around 30 minutes
It effectively "turns down the volume" on your hunger signals and cravings, making it much easier to eat smaller portions without feeling deprived
Long-term efficacy trajectories of GLP-1 receptor agonists: a systematic review and network meta-analysis, Diabetes, Metabolic Syndrome and Obesity (2025) The effect of early response to GLP-1 RA therapy on long-term adherence and persistence among Type 2 diabetes patients in the United States, Journal of Managed Care & Specialty Pharmacy (2019) Weight loss between glucagon-like peptide-1 receptor agonists and bariatric surgery in adults with obesity: A systematic review and meta-analysis, Obesity (2022) FDA approves first medication for obstructive sleep apnea, U.S